Dr. Philip Thorpe, Ph.D., lead researcher of the Bavituximab study [1] reviewed on this website, recently agreed to conduct an interview with The Behavioral Medicine Report. The original review of his research turned out to be a highly accessed article that justified a follow-up interview with Dr. Thorpe. I also wanted to clarify my understanding of Bavituximab and its treatment implications and to better determine if the excitement that surrounds Bavituximab is justified.
Latent viruses and their damaging effects and possible cures are an intense focus of current research efforts. I not aware of any cure for these elusive latent viruses, who are virtually undetectable by the immune system during latent stages. Examples of latent viruses include herpes, Epstein Bar, and Cytomegalovirus. Latent viruses are suspected, and occasionally proven, to be casual or contributing factors to mental/developmental disorders, such as autism and schizophrenia and to physical disorders like high blood pressure and atherosclerosis (see the first link).